Key result
A robust computational sampling of microarray data identified interferon-gamma signaling and CD8 T cell-mediated immune responses as key altered pathways in Inclusion Body Myositis, proposing several candidate drugs for repositioning.
Why the study?
The study was conducted to establish a robust methodology to address phenotype prediction problems associated with drug repositioning in rare diseases.
A robust computational sampling methodology identified novel altered pathways and potential repositionable drugs for Inclusion Body Myositis, which require further preclinical and clinical validation.
Answers are grounded in this paper and cite their sources.
Does not support clinical use in inclusion body myositis; leaves open drug repositioning pending validation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Fernández‐Martínez et al. (2019) studied Inclusion Body Myositis (n=34). Robust sampling of altered pathways (computational analysis) vs. Healthy controls was evaluated on Identification of altered genetic pathways and candidate repositioned drugs. A robust computational sampling of microarray data identified interferon-gamma signaling and CD8 T cell-mediated immune responses as key altered pathways in Inclusion Body Myositis, proposing several candidate drugs for repositioning.
Synapse has enriched 10 related papers. Consider them for comparative context: